IDEX Q4 sales rise 4%, beat expectations

Reuters
Feb 04
IDEX Q4 sales rise 4%, beat expectations

Overview

  • Engineered products firm's Q4 sales rose 4%, beating analyst expectations

  • Adjusted EPS for Q4 increased 3%, beating analyst expectations

  • Company utilized $73 mln for share repurchases in Q4

Outlook

  • IDEX expects full-year 2026 organic sales to rise 1% to 2%

  • Company forecasts 2026 adjusted diluted EPS of $8.15 to $8.35

  • IDEX projects Q1 2026 organic sales to increase about 1% from prior year; sees adjusted diluted EPS of $1.73 to $1.78

Result Drivers

  • HST SEGMENT GROWTH - Order growth in HST segment driven by demand for AI-related projects, including data center power solutions and semiconductor applications

  • OPERATIONAL PRODUCTIVITY - Improved operational productivity and cost containment measures contributed to increased gross margin

  • SEGMENT CHALLENGES - FMT and FSDP segments faced lower volumes, partly offset by positive pricing strategies

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$899.10 mln

$882.43 mln (11 Analysts)

Q4 Adjusted EPS

Beat

$2.10

$2.04 (11 Analysts)

Q4 EPS

$1.71

Q4 Adjusted Net Income

Beat

$157.20 mln

$153.06 mln (6 Analysts)

Q4 Adjusted EBITDA

Beat

$240.90 mln

$215.20 mln (2 Analysts)

Q4 Adjusted Gross Margin

43.10%

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

  • Wall Street's median 12-month price target for IDEX Corp is $201.00, about 0.3% below its February 3 closing price of $201.61

  • The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nBw4TP6qCa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10